Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 05, 2025 08:00 ET | Source: Vaxcyte, Inc.

Vaxcyte Advances to Second Stage of Ongoing Phase 2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Infants

-- Advancement to Stage 2 of Infant Study Supported by Review of Stage 1 Safety and Tolerability Data -- -- Company Expects to Announce VAX-31 Infant Study Topline Safety, Tolerability and...
January 30, 2025 16:05 ET | Source: Vaxcyte, Inc.

Vaxcyte to Present at the Guggenheim SMID Cap Biotech Conference

SAN CARLOS, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the...
December 03, 2024 08:00 ET | Source: Vaxcyte, Inc.

Vaxcyte Initiates Phase 2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Infants

-- Company Expects to Announce VAX-31 Infant Study Topline Safety, Tolerability and Immunogenicity Data from Primary Immunization Series in Mid-2026, Followed by Topline Data from the Booster Dose...
November 12, 2024 07:30 ET | Source: Vaxcyte, Inc.

Vaxcyte Provides Positive Regulatory Updates on VAX-31 Pediatric and Adult Programs

-- VAX-31 Infant Indication: Investigational New Drug Application Cleared by FDA; Company Expects to Initiate VAX-31 Infant Phase 2 Study by the End of January 2025 -- -- VAX-31 Adult Indication:...
November 05, 2024 16:01 ET | Source: Vaxcyte, Inc.

Vaxcyte Reports Third Quarter 2024 Financial Results and Provides Business Update

-- Company Reported Positive Topline Safety, Tolerability and Immunogenicity Data from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate, in Adults Aged 50 and...
September 11, 2024 16:05 ET | Source: Vaxcyte, Inc.

Vaxcyte to Present at the 2024 Cantor Global Healthcare Conference

SAN CARLOS, Calif., Sept. 11, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the...
September 06, 2024 16:05 ET | Source: Vaxcyte, Inc.

Vaxcyte Announces Closing of $1.5 Billion Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

SAN CARLOS, Calif., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the...
September 04, 2024 23:58 ET | Source: Vaxcyte, Inc.

Vaxcyte Announces Pricing of $1.3 Billion Public Offering

SAN CARLOS, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the...
September 03, 2024 16:01 ET | Source: Vaxcyte, Inc.

Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants

SAN CARLOS, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the...
September 03, 2024 07:07 ET | Source: Vaxcyte, Inc.

Vaxcyte Reports Positive Topline Data from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older

-- At All Doses Studied, VAX-31 Demonstrated Robust Opsonophagocytic Activity Immune Responses for All 31 Serotypes -- -- At Middle and High Doses, VAX-31 Met or Exceeded Regulatory Immunogenicity...